Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two antifungal pills go head to head against a fungus that scars the lungs

NCT ID NCT07825259

Disease control Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers compare two oral antifungal medicines, itraconazole and posaconazole, in people with chronic pulmonary aspergillosis, a fungal infection that damages the lungs over time. The trial enrolls 220 adults who have not yet received antifungal treatment and assigns them to one of the two drugs for 12 months. Doctors track whether symptoms and chest CT scans improve or stay stable, and they monitor side effects. The goal is to learn which drug works better and to guide treatment choices for this neglected disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two oral antifungal medicines, itraconazole and posaconazole
What this could lead to
If one drug works better or is safer, doctors could tailor treatment for a fungal lung disease that often goes overlooked.
What could go wrong
The two drugs may perform similarly, so the comparison may not change practice. Antifungals can cause side effects, and the fungus may resist treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * One or more clinical symptoms (persistent cough, recurrent haemoptysis, weight loss, malaise, fever, dyspnoea) for ≥3 months * Slowly progressive or persistent radiological findings on CT thorax including one or more cavities with or without a fungal ball, fibrosis, pericavitary infiltrates, consolidation, nodules, or pleural thickening * Serum A. fumigatus-IgG ≥27 milligrams of antibody/litre (mgA/L), or growth of Aspergillus in respiratory secretions (twice in sputum or once in bronchoalveolar lavage fluid \[BALF\]) or serum galactomannan index (GMI) ≥1.7 or BALF GMI ≥2.6. * Exclusion of other pulmonary disorders with similar presentation (active pulmonary TB, malignancy, other infections) Exclusion Criteria: * Failure or refusal to provide written informed consent * Patients on immunosuppressive drugs, receiving prednisolone (or equivalent) ≥10 mg/day for ≥3 weeks, or known HIV infection * Intake of antifungal triazoles for ≥3 weeks in the preceding 3 months (prior azole therapy) * Active pulmonary infection due to Mycobacterium tuberculosis or non-tuberculous mycobacteria * Other forms of pulmonary aspergillosis (subacute or acute invasive aspergillosis) * Pregnancy or lactation * Significant hepatic dysfunction (ALT/AST ≥3× upper limit of normal at baseline) * Known hypersensitivity to azole antifungals

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pulmonary aspergillosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aspergillosis pulmonary aspergilloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pulmonary aspergillosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chest Clinic, PGIMER, Chandigarh

    Chandigarh, Chandigarh, 160012, India

  • Chest Clinic, PGIMER, Chandigarh

    Chandigarh, Chandigarh, 160012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.